aid: jnana-therapeutics name: Jnana Therapeutics description: >- Jnana Therapeutics Inc. is a biotechnology company headquartered at One Design Center Place, Suite 19-400, Boston, Massachusetts, that built RAPID — Reactive Affinity Probe Interaction Discovery — a next-generation chemoproteomics platform for discovering small-molecule medicines against target classes that conventional screening has struggled to drug, including SLC transporters, transcription factors, signaling scaffold proteins, phosphatases, GPCRs and helicases. RAPID runs in living cells: a proprietary Reactive Affinity Probe library covalently labels druggable pockets on a validated target, and a proprietary detection technology then screens large drug-like compound libraries for binders that displace the probe, yielding allosteric inhibitors, localization modulators and molecular glues without iterative structural biology. Its internal pipeline focuses on phenylketonuria (PKU) — where JNT-517, an oral inhibitor acting at a cryptic allosteric site on the SLC6A19 transporter, reached Phase 1b/2 — and on immune-mediated diseases including targets such as interferon regulatory factor 3 (IRF3), alongside biopharma collaborations that include Roche. Otsuka Pharmaceutical Co., Ltd. completed its acquisition of Jnana on 23 September 2024 for $800 million plus up to $325 million in development and regulatory milestones, making Jnana a direct subsidiary of Otsuka America, Inc.; Otsuka initiated a global Phase 3 trial of repinatrabit in PKU in December 2025. Jnana Therapeutics runs no developer program and publishes no product API, developer portal, API reference or SDK. The only machine-readable surface reachable without credentials is the WordPress REST content API behind www.jnanatx.com, catalogued here. image: https://www.jnanatx.com/wp-content/uploads/2022/09/cropped-android-chrome-512x512-1.png url: https://raw.githubusercontent.com/api-evangelist/jnana-therapeutics/refs/heads/main/apis.yml x-type: company x-source: harvest:secondary-market x-tier: profiled x-tier-reason: enriched specificationVersion: '0.23' created: '2026-08-23' modified: '2026-08-23' tags: - Company - Biotechnology - Pharmaceuticals - Drug Discovery - Chemoproteomics - Rare Disease - Immunology - Life Sciences - Clinical Trials - content-api tags_raw: - Company - biotechnology - pharmaceuticals - drug-discovery - chemoproteomics - rare-disease - immunology - life-sciences - clinical-trials - content-api apis: - aid: jnana-therapeutics:jnana-therapeutics-content-api name: Jnana Therapeutics Content API description: >- The read-only WordPress REST content surface behind www.jnanatx.com — news posts (62), corporate pages (9), media (376), post categories (7), the `team` custom post type (9 profiles) and its `team-department` taxonomy (4 terms), cross-content search, oEmbed 1.0, Yoast SEO head metadata and Genesis theme documents. Verified anonymously reachable on 2026-08-23; an OPTIONS preflight returns `allow: GET`, and every write and administrative route answers 401/403/404 without credentials. Jnana publishes no OpenAPI or API reference for this surface — the OpenAPI here is an API Evangelist derivation of the live route index, and humanURL points at the upstream WordPress REST handbook that defines the wp/v2 contract. humanURL: https://developer.wordpress.org/rest-api/ baseURL: https://www.jnanatx.com/wp-json tags: - Content - Posts - Pages - Media - Taxonomy - Team - Search - oEmbed tags_raw: - content - posts - pages - media - taxonomy - team - search - oembed properties: - type: OpenAPI url: openapi/jnana-therapeutics-content-openapi.yml - type: Overlay url: overlays/jnana-therapeutics-content-overlay.yaml - type: Authentication url: authentication/jnana-therapeutics-authentication.yml - type: Conventions url: conventions/jnana-therapeutics-conventions.yml - type: ErrorCatalog url: errors/jnana-therapeutics-problem-types.yml - type: DataModel url: data-model/jnana-therapeutics-data-model.yml - type: RateLimits url: rate-limits/jnana-therapeutics-rate-limits.yml maintainers: - FN: Kin Lane email: kin@apievangelist.com - FN: APIs.json email: info@apis.io common: - type: DomainSecurity url: security/jnana-therapeutics-domain-security.yml - type: Website url: https://www.jnanatx.com/ - type: Platform url: https://www.jnanatx.com/rapid-platform/ - type: Programs url: https://www.jnanatx.com/programs/ - type: Team url: https://www.jnanatx.com/team/ - type: News url: https://www.jnanatx.com/news/ - type: BlogRSS url: https://www.jnanatx.com/feed/ - type: Careers url: https://www.jnanatx.com/join-us/ - type: ContactUs url: https://www.jnanatx.com/contact-us/ - type: PrivacyPolicy url: https://www.jnanatx.com/privacy-policy/ - type: TermsOfService url: https://www.jnanatx.com/terms-of-use/ - type: LinkedIn url: https://www.linkedin.com/company/jnana-therapeutics/ - type: X url: https://x.com/jnanatx - type: ParentCompany url: https://www.otsuka.co.jp/en/ - type: SecondaryMarket url: https://forgeglobal.com/jnana-therapeutics_stock/ - type: Authentication url: authentication/jnana-therapeutics-authentication.yml - type: Conventions url: conventions/jnana-therapeutics-conventions.yml - type: Conformance url: conformance/jnana-therapeutics-conformance.yml - type: ErrorCatalog url: errors/jnana-therapeutics-problem-types.yml - type: Lifecycle url: lifecycle/jnana-therapeutics-lifecycle.yml - type: DataModel url: data-model/jnana-therapeutics-data-model.yml - type: Overlay url: overlays/jnana-therapeutics-content-overlay.yaml - type: Packages url: packages/jnana-therapeutics-packages.yml - type: RateLimits url: rate-limits/jnana-therapeutics-rate-limits.yml - type: Plans url: plans/jnana-therapeutics-plans-pricing.yml - type: LLMsTxt url: llms/jnana-therapeutics-llms.txt - type: AgentSkill url: skills/_index.yml x-enrichment: date: '2026-08-23' status: enriched artifacts_added: 18 pass: local-v1